Qyuns Therapeutics Co., Ltd. (Stock Code: 2509) announced that a total of 2,487,800 ordinary shares were repurchased on The Stock Exchange of Hong Kong Limited between November 6, 2025, and the date of the announcement. These repurchased shares, held as treasury shares, represent approximately 1.10% of the existing total issued share capital.

The total amount involved, excluding commission and associated expenses, is approximately HK$50.75 million. The board of directors considers the current share price to significantly undervalue the company’s worth and aims to bolster market confidence and investment value through the execution of this on-market share repurchase under the mandate approved at the annual general meeting on June 20, 2025.

The exact timing, quantity, and price of further share repurchases are subject to market conditions and fall under the discretion of the board of directors or its authorized persons.